BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

D-Pharm Ltd. Receives First Payment for Epilepsy Drug, DP-VPA From Its Chinese Partner


5/3/2012 12:27:25 PM

Rehovot, Israel May 3rd, 2012 -- D-Pharm Ltd., (TASE: DPRM) announced today that it has received the first payment of $1M from Jiangsu NHWA Pharmaceutical Co., Ltd. (NHWA) in relation to DP-VPA development for epilepsy in China. NHWA is the leading Chinese company developing and marketing drugs to treat CNS disorders in China.

DP-VPA is a novel drug discovered and developed by D-Pharm; a derivative of the generic drug valproic acid which has sales over $1B for treatment of patients with epilepsy, migraine and bipolar disorder. DP-VPA has already completed a first Phase II study in epilepsy patients.

D-Pharm and NHWA entered into a strategic agreement in May 2011. According to the agreement, NHWA assumed the responsibility for development, manufacturing, registration and marketing of DP-VPA for epilepsy in China, Hong Kong and Macau. NHWA is committed to develop DP-VPA in China in compliance with US FDA standards. D-Pharm has the right to use data produced in China towards the global development effort outside China.

D-Pharm is entitled to receive cumulatively $2.4M, including the current $1M, as R&D funding and a development milestones. In addition to milestone payments and fulfillment of the research and development objectives, D-Pharm may receive royalty payments (5%), subject to certain conditions stipulated in the agreement and D-Pharm will pay NHWA royalty payments (0.1%) from worldwide sales outside China. At present, D-Pharm is progressing with the development and testing in healthy volunteers of novel a tablet formulation of DP-VPA. Completion of this task will pave the way for Phase II clinical studies both in epilepsy (China) and migraine (ROW) patients.

Approximately 50 million people worldwide suffer from epilepsy, with around 30% not responding to existing marketed therapies. In addition, for many patients, current therapies induce severe side effects including tremor, somnolence, weight gain and liver damage.

D-Pharm believes that DP-VPA has the potential to be beneficial for patients with epilepsy, migraine and bipolar disorder.

About D-Pharm

D-Pharm (www.dpharm.com) is a clinical stage, technology-driven biopharmaceutical company developing proprietary products for treatment of CNS disorders. D-Pharm’s pipeline includes clinical stage II products, as well as a rich preclinical development pipeline for Alzheimer's disease, dementia and ALS.

D-Pharm was established in 1993 by Dr. Alex Kozak, President and CEO.In August 2009 the Company completed the first offering of its shares on the Tel Aviv stock exchange.

About NHWA

NHWA is a leading Chinese pharmaceutical company, engaged in developing cures for central nervous system disorders. The company develops anesthetics, anti-epilepsy drugs and drugs to treat pain.

For further information please contact:

Tami Horovitz

Tel: +972-8-9385100

Fax: +972-8-9300795

Email: thorovitz@dpharm.com

Disclaimer

Statements in this press release that are not historical facts are forward-looking information, as defined in the Securities Law, based on information available to D-Pharm at the time of this press release. The estimations could, some or all, be unrealized, or could be realized in significantly different ways than expected.



Read at BioSpace.com

   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES